Characterization of an APP/tau rat model of Alzheimer's disease by positron emission tomography and immunofluorescent labeling.
Alzheimer’s disease
Immunohistochemistry
Rat model
[11C]PiB
[18F]THK-5317
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
16 10 2021
16 10 2021
Historique:
received:
07
06
2021
accepted:
05
10
2021
entrez:
17
10
2021
pubmed:
18
10
2021
medline:
29
10
2021
Statut:
epublish
Résumé
To better understand the etiology and pathomechanisms of Alzheimer's disease, several transgenic animal models that overexpress human tau or human amyloid-beta (Aβ) have been developed. In the present study, we generated a novel transgenic rat model by cross-breeding amyloid precursor protein (APP) rats with tau rats. We characterized this model by performing positron emission tomography scans combined with immunofluorescent labeling and cerebrospinal fluid analyses. APP/Tau rats were generated by cross-breeding male McGill-R-Thy1-APP transgenic rats with female hTau-40/P301L transgenic rats. APP/Tau double transgenic rats and non-transgenic (ntg) littermates aged 7, 13, and 21 months were subjected to dynamic [ [ We thoroughly characterized a novel APP/Tau rat model using combined PET imaging and immunofluorescence analysis. We observed an age-related increase in [
Sections du résumé
BACKGROUND
To better understand the etiology and pathomechanisms of Alzheimer's disease, several transgenic animal models that overexpress human tau or human amyloid-beta (Aβ) have been developed. In the present study, we generated a novel transgenic rat model by cross-breeding amyloid precursor protein (APP) rats with tau rats. We characterized this model by performing positron emission tomography scans combined with immunofluorescent labeling and cerebrospinal fluid analyses.
METHODS
APP/Tau rats were generated by cross-breeding male McGill-R-Thy1-APP transgenic rats with female hTau-40/P301L transgenic rats. APP/Tau double transgenic rats and non-transgenic (ntg) littermates aged 7, 13, and 21 months were subjected to dynamic [
RESULTS
[
CONCLUSIONS
We thoroughly characterized a novel APP/Tau rat model using combined PET imaging and immunofluorescence analysis. We observed an age-related increase in [
Identifiants
pubmed: 34656177
doi: 10.1186/s13195-021-00916-2
pii: 10.1186/s13195-021-00916-2
pmc: PMC8522096
doi:
Substances chimiques
Amyloid beta-Peptides
0
Amyloid beta-Protein Precursor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
175Informations de copyright
© 2021. The Author(s).
Références
Behav Res Methods. 2009 Nov;41(4):1149-60
pubmed: 19897823
J Neurosci. 2013 Apr 10;33(15):6245-56
pubmed: 23575824
J Alzheimers Dis. 2006;9(3 Suppl):151-3
pubmed: 16914853
Brain Res. 2007 Mar 30;1139:60-7
pubmed: 17292334
Mol Psychiatry. 2021 Oct;26(10):5481-5503
pubmed: 34456336
J Neurosci. 2017 Dec 13;37(50):12263-12271
pubmed: 29097597
Neurobiol Aging. 2004 Jul;25(6):697-711
pubmed: 15165691
J Nucl Med. 2014 Sep;55(9):1532-8
pubmed: 24963128
Acta Neuropathol Commun. 2019 Mar 11;7(1):37
pubmed: 30857558
J Neuropathol Exp Neurol. 1997 Oct;56(10):1095-7
pubmed: 9329452
Curr Neuropharmacol. 2017;15(6):926-935
pubmed: 28093977
Neurobiol Aging. 2012 Jul;33(7):1448-56
pubmed: 21196063
Eur J Neurol. 2010 Oct;17(10):1236-48
pubmed: 20831773
J Alzheimers Dis. 2010;20(1):113-26
pubmed: 20164597
Alzheimers Dement. 2013 Nov;9(6):666-76
pubmed: 23411393
EMBO Mol Med. 2009 Nov;1(8-9):371-80
pubmed: 20049742
Curr Pharm Des. 2004;10(13):1469-92
pubmed: 15134570
Mol Imaging Biol. 2020 Apr;22(2):223-244
pubmed: 31168682
Mol Psychiatry. 2004 Jul;9(7):664-83
pubmed: 15052274
ASN Neuro. 2009 Nov 09;1(4):
pubmed: 19839939
Science. 1992 Apr 10;256(5054):184-5
pubmed: 1566067
Transgenic Res. 1996 Jul;5(4):223-34
pubmed: 8755162
J Nucl Med. 2005 Mar;46(3):455-63
pubmed: 15750159
Alzheimers Res Ther. 2017 Mar 31;9(1):25
pubmed: 28359327
Neurobiol Aging. 2011 Dec;32(12):2314-5
pubmed: 20097445
J Neurochem. 1979 Apr;32(4):1249-57
pubmed: 372497
Appl Radiat Isot. 2005 Apr;62(4):591-5
pubmed: 15701414
Nat Rev Neurosci. 2018 Oct;19(10):583-598
pubmed: 30194347
Chem Pharm Bull (Tokyo). 2003 Apr;51(4):409-11
pubmed: 12672993
Science. 2001 Aug 24;293(5534):1487-91
pubmed: 11520987
Eur J Neurosci. 2008 Jul;28(2):239-46
pubmed: 18702695
Science. 2001 Aug 24;293(5534):1491-5
pubmed: 11520988
J Nucl Med. 2013 Aug;54(8):1420-7
pubmed: 23857514
J Labelled Comp Radiopharm. 2014 Jan;57(1):18-24
pubmed: 24448742
NeuroRx. 2005 Jul;2(3):423-37
pubmed: 16389306
J Nucl Med. 2016 May;57(5):792-8
pubmed: 26912432
PLoS Biol. 2020 Jul 14;18(7):e3000411
pubmed: 32663221
Nucl Med Biol. 2020 May - Jun;84-85:28-32
pubmed: 31981857
Brain. 2021 Sep 4;144(8):2284-2290
pubmed: 33742656
Theranostics. 2021 May 3;11(14):6644-6667
pubmed: 34093845
Ann Neurol. 2004 Mar;55(3):306-19
pubmed: 14991808